Fiona C. Baker, PhD, discusses the clinical presentation and diagnosis of vasomotor symptoms, interprets new phase 3 data on elinzanetant, and provides guidance to help clinicians confidently manage VMS and navigate emerging non-hormonal treatment options.
E. Michael Lewiecki, MD, discusses how menopause significantly impacts bone health through increased bone remodeling and loss, while exploring promising new neurokinin-targeted therapies like elinzanetant that may simultaneously treat vasomotor symptoms and provide skeletal benefits, as demonstrated in the OASIS-3 trial's subanalysis showing improved bone mineral density, reduced bone turnover markers, and favorable body composition changes compared with placebo.
A panelist highlights that new nonhormonal treatments show promising, well-tolerated relief of persistent vasomotor symptoms (VMS) in patients with hormone receptor–positive breast cancer receiving endocrine therapy, improving quality of life and adherence while ongoing research addresses long-term safety and underserved populations.
